[ customers have already purchased this product.]   
Share |

Product name : FG-2216

Product description :
Recently several drugs have been developed which act as selective HIF prolyl-hydroxylase inhibitors. The most notable of these include FibroGen's compounds FG-2216 and FG-4592,both are intended as orally acting drugs for use in the treatment of forms of anemia. By inhibiting HIF prolyl-hydroxylase, the activity of HIF-1α in the bloodstream is prolonged, which results in an increase in endogenous production of erythropoetin.A new drug called FG-2216 can stimulate production of the hormone erythropoietin (EPO) in dialysis patients—possibly offering a new approach to treatment of kidney disease-related anemia, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

Please feel free to FG-2216for: FG-2216 Quotation ( FG-2216 suppliers),COA (Certificate of Analysis), New Sales Promotion,New Products,And any other assistance. FG-2216

Send to this supplier

 After send online enquiry, we will reply you as soon as possible, if not get any response on time please contact us by Tel or Email.
1. Email: sales@Greenstoneswiss.com
2. Tel: +86 592 5365887
3. WhatsApp: +86 189 6515 7632
4. Send enquiry online:


Customer also maybe viewed the follwing products

Product Image

  • Calcium sulfate
  • Pyridostigmine Deuterated
  • Lauryl glucoside
  • Agrimory Extract
  • Order

    Email us
    Email us
    Email us
    Email us
    Contact Us

    Green Stone Swiss Co ., ltd.

    Email: sales@greenstoneswiss.com

    Tel: +86 592 5365887 

    WhatsApp: +86 189 6515 7632 

    Send an Inquiry, get a discount and complete services.